GDNF-Based Therapy Shows Promising Metabolic Benefits in Preclinical MASLD Study

GDNF-Based Therapy Shows Promising Metabolic Benefits in Preclinical MASLD Study

By, Admin 11 March 2026

New preclinical research suggests that a GDNF-based therapy could improve lipid metabolism and protect liver function in obesity-related metabolic disease.

Hoth Therapeutics recently reported female-specific results from the second phase of its metabolic disease study evaluating HT-VA, a treatment based on glial cell-derived neurotrophic factor (GDNF).

The findings show improvements in cholesterol levels, triglycerides, and liver cellular pathways in mice fed a western diet—a model commonly used to study Metabolic Dysfunction-Associated Steatotic Liver Disease.

These results support further development of HT-VA for metabolic dysfunction linked to obesity and liver disease.

Study Overview

The second phase of the study focused specifically on female mice, which were fed a western diet for eight weeks to induce metabolic dysfunction.

Researchers then administered treatments for four weeks, including:

  • GDNF therapy (HT-VA)
  • Semaglutide
  • Vehicle control

Scientists evaluated:

  • Serum liver biochemistry
  • Lipid metabolism biomarkers
  • Hepatic protein expression
  • Cellular pathways related to autophagy and lipid accumulation

Each treatment group contained 8–10 animals, and results were reported as mean ± SEM.

GDNF Restores Cholesterol Levels in Western Diet–Fed Mice

Female mice on a western diet developed elevated cholesterol levels compared with animals fed a standard control diet. However, mice treated with GDNF showed a reversal of this effect.

The therapy restored cholesterol levels to ranges comparable with control-diet animals, indicating improved lipid metabolism despite the high-fat dietary environment.

Lower Triglycerides Compared With Semaglutide

The study also revealed differences in triglyceride levels between treatments. Key findings included:

  • Western diet mice treated with semaglutide showed increased triglyceride levels
  • Mice receiving GDNF therapy maintained lower triglyceride levels

This suggests that the GDNF-based treatment may produce a more favorable lipid profile in this metabolic disease model.

Liver Function Markers Remained Stable

Researchers also assessed biochemical markers linked to liver health. Two key markers remained stable across all treatment groups:

  • Albumin (ALB) – a marker of liver synthetic function
  • Alkaline phosphatase (ALP) – an enzyme linked to bile duct function and liver injury

The absence of significant changes indicates that liver synthetic function remained stable during treatment.

GDNF Preserves Hepatic Autophagy

Autophagy plays a crucial role in maintaining healthy liver cells by removing damaged proteins and organelles.

The study evaluated p62/SQSTM1, a protein that accumulates when autophagy is impaired.

Findings showed:

  • Semaglutide increased p62 levels, suggesting impaired autophagic degradation
  • GDNF treatment did not increase p62 expression

These results suggest that GDNF preserved normal cellular recycling pathways in liver tissue.

No Activation of Lipogenesis Pathways

Researchers also examined proteins involved in fat accumulation in the liver.

Two important markers were analyzed:

  • PPARγ – associated with lipid storage and fat cell development
  • CD36 – involved in fatty acid uptake into liver cells

The study found no change in expression of either protein in GDNF-treated mice.

This suggests that GDNF improved metabolic biomarkers without activating pathways that promote fat accumulation in the liver.

Distinct Molecular Signaling Compared With Semaglutide

The study also revealed differences in cellular signaling between treatments. Mice treated with semaglutide showed:

  • Increased AKT phosphorylation (pAKT) in liver tissue

In contrast, GDNF treatment did not significantly alter AKT signaling, indicating a different molecular mechanism of action.

Implications for Metabolic Liver Disease

These findings suggest that GDNF therapy may address several key aspects of metabolic dysfunction simultaneously:

  • Improved cholesterol metabolism
  • Lower triglyceride levels
  • Preservation of autophagy in liver cells
  • Stable liver function markers
  • No activation of lipogenic pathways

Together, these results support continued development of HT-VA as a potential therapy for metabolic disease linked to obesity.

What Comes Next?

While these results come from preclinical animal models, they provide early evidence that GDNF-based therapies could offer a new mechanistic approach to treating metabolic liver disease.

As research progresses, further studies will be needed to determine whether these metabolic and cellular benefits translate into clinical outcomes in humans.

For now, the data highlight the potential of HT-VA as an emerging candidate in the growing field of therapies targeting metabolic dysfunction and MASLD.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!